Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage. - Wikidata - awgldk - TriplyDB

Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

http://www.wikidata.org/entity/Q30300218

about

Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and Development Metabolomics for clinical use and research in chronic kidney disease.NRF2 PREVENTS HYPERTENSION, INCREASED ADMA, MICROVASCULAR OXIDATIVE STRESS AND DYSFUNCTION IN MICE WITH TWO WEEKS OF ANGIOTENSIN II INFUSION.Regulation of fluid reabsorption in rat or mouse proximal renal tubules by asymmetric dimethylarginine (ADMA) & dimethylarginine dimethylaminohydrolase (DDAH) 1.

P2860

Q28070134-E27BFDFB-9634-4EDA-8D89-814D40D264AB Q38750287-3595EB96-BAAE-4D9B-B66E-85902BDFBF3E Q46255801-AF1D8FD1-0154-4580-B77F-62F421FAADB0 Q52669796-2EBD1597-2D84-43A5-B5CA-824D16B80A0A

P2860

Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

http://www.wikidata.org/entity/Q30300218

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

@ast

Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

@en

type

label

Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

@ast

Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

@en

prefLabel

Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

@ast

Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

@en

P1433

Q30300218-67EAF9E7-15EF-468D-B582-758794E1D5B3

P1476

Q30300218-B1D7B141-5781-4862-99C0-04FA1EC578B9

P2093

Q30300218-5D3E2768-E109-48CE-9EC4-6BAA0B6ADD39

Q30300218-6EFA2298-F3E5-469B-A5F5-CD6F6BA6CB36

Q30300218-7635E177-D913-4E01-876D-EAC3E924CB33

Q30300218-9DB5B823-4224-4EC8-8411-FFF9EF89BA8E

Q30300218-A1E18152-8EF4-443E-A662-A30FE9696D76

Q30300218-B8791D67-03E3-4F82-892D-6FA60EC68888

Q30300218-C18A0C1D-7A9D-4927-9953-EAFB5CE87E7E

Q30300218-CF8D601F-52DF-4180-B462-400B880FC851

Q30300218-DDDB29D4-B97F-45D9-9EAB-83B4FF7BBBB3

Q30300218-E4A6509E-8DB9-4DA0-A334-2FDA75D866BD

P2860

Q30300218-080090C2-E412-490A-B299-E8D2F326D96E

Q30300218-0A9AD74A-F857-4E2A-B52F-84B73EEB213D

Q30300218-1510BD7C-EA3D-4292-A024-BF10848B7DB0

Q30300218-151E006A-6D5B-44A8-B678-DF9561025381

Q30300218-19694456-9141-4B0C-BCBB-F7A18D1A17F4

Q30300218-1E7D0EE5-B23B-4E4A-BF6D-E7F2016BBD2F

Q30300218-23F4667B-72C8-4B06-96B3-B5BD3CE9AE06

Q30300218-270A76D5-B618-4231-9AA8-8C4E6A8529C3

Q30300218-2B0752FF-8E8E-4BB6-A983-1E9A8AD95616

Q30300218-2B3B0033-236A-4093-9C70-4E52A2A270F9

P304

Q30300218-4266F1B9-F08B-4181-8CB2-D298BA5520E2

P31

Q30300218-488994C3-821B-4D7C-A4F2-C000EE6CDA32

P356

Q30300218-4C10142C-25A3-4D3D-93AD-40BCC19E0D5E

P433

Q30300218-BABA99FB-23AA-454D-9C0C-2F541720EA8F

P478

Q30300218-27DFB0C8-67EA-4F05-A5B4-55DDC7748FA2

P50

Q30300218-02388CE2-1965-4579-AE62-5EE8A35C1CC1

Q30300218-76E60A59-99CD-44FE-825D-D7C6D4AC0E9A

Q30300218-8A570DCE-499A-4FF4-9B76-ECD3A9DEE1AA

Q30300218-B2D5B190-3E3F-4804-8871-8370AEF55C87

Q30300218-DAEA2AB4-D2C3-4D2C-BF92-E0667F31EC5B

P577

Q30300218-D5993EC7-2BFA-4A94-8DE0-FD9289FE5ABE

P698

Q30300218-77248E09-F766-4A95-8775-03F4DB8493E0

P932

Q30300218-0BA01F63-657E-4661-95D6-15382D05C3AF

P356

P1433

Journal of the American Society of Nephrology

P1476

Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

@en

P2093

Christopher S Wilcox

http://www.w3.org/2001/XMLSchema#string

Claire Bruce-Cobbold

http://www.w3.org/2001/XMLSchema#string

David C Wheeler

http://www.w3.org/2001/XMLSchema#string

Dirk Dormann

http://www.w3.org/2001/XMLSchema#string

Dorothea D Nitsch

http://www.w3.org/2001/XMLSchema#string

James A P Tomlinson

http://www.w3.org/2001/XMLSchema#string

Jill T Norman

http://www.w3.org/2001/XMLSchema#string

Olga Boruc

http://www.w3.org/2001/XMLSchema#string

Sanjay Khadayate

http://www.w3.org/2001/XMLSchema#string

Valeria R Mas

http://www.w3.org/2001/XMLSchema#string

P2860

Nitric oxide: physiology, pathophysiology, and pharmacology

Nitric oxide synthase derangements and hypertension in kidney disease

Disruption of methylarginine metabolism impairs vascular homeostasis

Nitric oxide enhances collagen synthesis in cultured human tendon cells

Superoxide dismutase 1 limits renal microvascular remodeling and attenuates arteriole and blood pressure responses to angiotensin II via modulation of nitric oxide bioavailability

Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression

Quantitative amino acid and proteomic analysis: very low excretion of polypeptides >750 Da in normal urine.

Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study.

Nitric oxide in the control of renal hemodynamics and excretory function.

Alanine-glyoxylate aminotransferase-2 metabolizes endogenous methylarginines, regulates NO, and controls blood pressure.

P304

3045-3059

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2014030280

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Pedro R Cutillas

Rebecca C Grossman

P577

2015-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25855779

http://www.w3.org/2001/XMLSchema#string

P932

4657823

http://www.w3.org/2001/XMLSchema#string